<DOC>
	<DOCNO>NCT00655564</DOCNO>
	<brief_summary>The purpose research study see well medication Alefacept ( Amevive® ) work continuous treatment chronic plaque psoriasis . The US Food Drug Administration ( FDA ) approve Alefacept intermittent dosage schedule 15 mg weekly injection 12 week follow 12 week treatment .</brief_summary>
	<brief_title>Long-Term One Year Use Alefacept ( Amevive® ) Moderate Severe Chronic Plaque Type Psoriasis</brief_title>
	<detailed_description>To estimate efficacy continuous use alefacept ( 15mg IM/week ) treatment moderate severe chronic plaque type psoriasis define Investigator Global Assessment ( IGA ) 0 1 ( clear almost clear ) 75 % reduction Psoriasis Area Severity Index ( PASI ) .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Must give write informed consent . Subjects must 18 year age old . Subject must adult male nonpregnant , nonlactating female . Female subject childbearing potential must state use measure avoid conception active mean include hormone replacement , intrauterine device , abstinence . Subjects must general good health skin disease , disease state physical condition would impair evaluation psoriasis would increase health risk study participation . Subjects must willing receive IM injection per protocol 1 year . Must require systemic therapy phototherapy psoriasis , determine investigator prior Visit 1 . Objectively equate Inclusion criterion either : IGA≥3 05 scale BSA≥10 % PASI ≥12 Subjects may take systemic therapy receive phototherapy duration study . Subjects require 4 week washout period systemic medication phototherapy prior enrol study start treatment alefacept . There washout topical corticosteroid medication . Stable dose topical corticosteroid may use first dose visit . Female subject postmenopausal least 1 year , surgically sterile , willing practice effective contraception study . Nursing mother , pregnant woman woman plan become pregnant study exclude . Subjects guttate , pustular , erythrodermic rapidly flare psoriasis . Current enrollment research study . Serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , pneumonia , septicemia ) within 3 month prior first dose investigational drug . Any subject CD4 &lt; 250 cells/µL study entry . Treatment another investigational drug approve therapy within 28 day prior study drug administration . Treatment systemic retinoids , systemic steroid , methotrexate , cyclosporine , azathioprine , thioguanine , etanercept , efalizumab , infliximab , adalimumab mofetil systemic immunosuppressant agent within 28 day prior investigational drug administration . Phototherapy , include Ultraviolet B ( UVB ) Psoralen + Ultraviolet A ( PUVA ) , within 28 day prior investigational drug administration . Known HIV+ , know viral Hepatitis infection , know tuberculosis infection . History systemic malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>